Comment
doi: 10.1038/s41571-022-00599-0.
HAIC-FO improves outcomes in HCC
Affiliations
- PMID: 35013583
- DOI: 10.1038/s41571-022-00599-0
Item in Clipboard
Comment
HAIC-FO improves outcomes in HCC
Nat Rev Clin Oncol.
2022 Mar.
No abstract available
Comment on
-
Arterial Chemotherapy of Oxaliplatin Plus Fluorouracil Versus Sorafenib in Advanced Hepatocellular Carcinoma: A Biomolecular Exploratory, Randomized, Phase III Trial (FOHAIC-1).J Clin Oncol. 2022 Feb 10;40(5):468-480. doi: 10.1200/JCO.21.01963. Epub 2021 Dec 14. J Clin Oncol. 2022. PMID: 34905388 Clinical Trial.
Similar articles
-
Sorafenib Plus Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin vs Sorafenib Alone for Hepatocellular Carcinoma With Portal Vein Invasion: A Randomized Clinical Trial.JAMA Oncol. 2019 Jul 1;5(7):953-960. doi: 10.1001/jamaoncol.2019.0250. JAMA Oncol. 2019. PMID: 31070690 Free PMC article. Clinical Trial.
-
Phase II Study of Sorafenib Combined with Concurrent Hepatic Arterial Infusion of Oxaliplatin, 5-Fluorouracil and Leucovorin for Unresectable Hepatocellular Carcinoma with Major Portal Vein Thrombosis.Cardiovasc Intervent Radiol. 2018 May;41(5):734-743. doi: 10.1007/s00270-017-1874-z. Epub 2018 Jan 11. Cardiovasc Intervent Radiol. 2018. PMID: 29327075 Clinical Trial.
-
Hepatic arterial infusion chemotherapy followed by sorafenib in patients with advanced hepatocellular carcinoma (HICS 55): an open label, non-comparative, phase II trial.BMC Cancer. 2018 Jun 4;18(1):633. doi: 10.1186/s12885-018-4519-y. BMC Cancer. 2018. PMID: 29866075 Free PMC article. Clinical Trial.
-
Sorafenib versus hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma: a systematic review and meta-analysis.Jpn J Clin Oncol. 2019 Sep 1;49(9):845-855. doi: 10.1093/jjco/hyz069. Jpn J Clin Oncol. 2019. PMID: 31063184
-
Systematic review of hepatic arterial infusion chemotherapy versus sorafenib in patients with hepatocellular carcinoma with portal vein tumor thrombosis.J Gastroenterol Hepatol. 2020 Aug;35(8):1277-1287. doi: 10.1111/jgh.15010. Epub 2020 Mar 3. J Gastroenterol Hepatol. 2020. PMID: 32052876
Cited by
-
Outcomes of Transarterial Embolisation (TAE) vs. Transarterial Chemoembolisation (TACE) for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis.Cancers (Basel). 2023 Jun 13;15(12):3166. doi: 10.3390/cancers15123166. Cancers (Basel). 2023. PMID: 37370776 Free PMC article. Review.
-
Efficacy and safety of HAIC combined with tyrosine kinase inhibitors versus HAIC monotherapy for advanced hepatocellular carcinoma: a multicenter propensity score matching analysis.Front Pharmacol. 2024 Jul 31;15:1410767. doi: 10.3389/fphar.2024.1410767. eCollection 2024. Front Pharmacol. 2024. PMID: 39144625 Free PMC article.
-
Prognosis prediction and risk stratification of transarterial chemoembolization or intraarterial chemotherapy for unresectable hepatocellular carcinoma based on machine learning.Eur Radiol. 2024 Aug;34(8):5094-5107. doi: 10.1007/s00330-024-10581-2. Epub 2024 Jan 30. Eur Radiol. 2024. PMID: 38291256 Free PMC article.
-
Adverse events associated with hepatic arterial infusion chemotherapy and its combination therapies in hepatocellular carcinoma: a systematic review.Front Immunol. 2025 Mar 3;16:1531249. doi: 10.3389/fimmu.2025.1531249. eCollection 2025. Front Immunol. 2025. PMID: 40098973 Free PMC article.
-
Histone lactylation promotes multidrug resistance in hepatocellular carcinoma by forming a positive feedback loop with PTEN.Cell Death Dis. 2025 Jan 31;16(1):59. doi: 10.1038/s41419-025-07359-9. Cell Death Dis. 2025. PMID: 39890782 Free PMC article.
References
Original article
-
- Lyu, N. et al. Arterial chemotherapy of oxaliplatin plus fluorouracil versus sorafenib in advanced hepatocellular carcinoma: a biomolecular exploratory, randomized, phase III trial (FOHAIC-1). J. Clin Oncol https://doi.org/10.1200/JCO.21.01963 (2021) - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
